On August 7, 2020 ABM Therapeutics of Shanghai reported that it completed a $20 million Series A+ round (Press release, ABM Therapeutics, AUG 7, 2020, View Source [SID1234563241]). Founded in 2015, ABM develops small molecule drugs that cross the blood-brain barrier. The company has one candidate, ABM-1310, in clinical trials for glioblastoma along with several preclinical projects that are designed to cross the blood-brain barrier and treat brain metastasis from melanoma, lung and breast cancer. The A+ round was led by Huachuang Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!